News | May 05, 2023
Nouscom reaches clinical phase II using ProBioGen’s AGE1.CR.pIX production platform
Nous-209 has been developed using the Nouscom's viral vector platform
Nous-209 has been developed using the Nouscom's viral vector platform
The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments
The receipt of this permission paves way for the launch of Trastuzumab deruxtecan (Enhertu) solution of 100mg/5mL in India
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
Bridging the gap between histopathology and molecular pathology
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
Apollo continues to invest in genomics technology and research for better patient care
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
Subscribe To Our Newsletter & Stay Updated
